A New Therapeutic Use of High-dose131I-MIBG Therapy as Consolidation Therapy in Pediatric Patients with High-risk Neuroblastoma: The Japanese experience

Purpose: Pediatric high-risk neuroblastoma patients have poor prognoses despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for high-risk neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose 131I-meta-iodo-benzyl-guanidine (131I-MIBG) against invisible tumor cells on 123I-MIBG scintigraphy in pediatric patients with high-risk neuroblastoma and ganglioneuroblastoma. Materials and Methods: From December 2009 to December 2014, there were nine high-risk pediatric neuroblastoma and one high-risk ganglioneuroblastoma pediatric patients with complete response to primary therapy in diagnostic 123I-MIBG scintigraphy. The nine who received high-dose 131I-MIBG therapy were included in this study. One pediatric patient who received lower-dose 131I-MIBG therapy (